A new antiretroviral medication, FTC (emtricitabine, Emtriva) was listed on the PBS and became available for S100 prescription from 1 April.

A controversial Cambodian trial of tenofovir for pre-exposure prophylaxis (PREP) is unlikely to proceed after sex workers and the Cambodian government claimed the trial did not include adequate safeguards for the health and human rights of the participants.

Australian researchers have teamed up with the US and Cambodia to conduct a study of the potential of the HIV antiviral tenofovir, taken daily, to prevent HIV infection in women at high risk.

Female sex workers, who in Cambodia currently stand up to a 26 percent chance of becoming HIV-infected within their first year working in the sex industry, will be invited to participate in a ground-breaking study which researchers acknowledge is challenging, but necessary.

We all want simpler treatment regimens with fewer side effects and no meal restrictions, right? Well how does once-a-day treatment sound? As PAUL KIDD reports, it may be closer than you think.

The major international AIDS conference for 2003 has ended with encouraging signs of growing international commitment to fight AIDS in the developing world, and with several promising medical developments.

The 10th Conference on Retroviruses and Opportunistic Infections took place in Boston in February. This annual conference is a very highly regarded event with a strong scientific focus, so it often produces a number of important advances in our understanding of HIV and its treatment, and this year was no exception.

Selected brief news items from the pages of Positive Living.

A report from the 8th European Conference on the Clinical Aspects and Treatment of HIV Infection, held in Athens, Greece in October, 2001.

NAPWA and AFAO welcome the announcement and launch last night of the Special Access Scheme for the investigational agent – Tenofovir, a once daily oral nucleotide reverse transcriptase inhibitor for the treatment of HIV.